Evidence is lining up for the likely fourth JAK inhibitor – with filgotinib shown to help treatment-refractory patients with moderate to severe active rheumatoid arthritis achieve a clinical response. A randomised controlled trial, published in JAMA, compared filgotinib at 100mg or 200mg once daily to placebo in 448 adult patients from 114 sites internationally, including ...
New JAK inhibitor filgotinib shows efficacy in RA: Prof Peter Nash
By Mardi Chapman
7 Aug 2019